Latest Shareholder Engagement News

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Alicanto Minerals is actively assessing new copper, gold, and silver projects while preparing for a key summer field program in Sweden, supported by a solid cash position of $2.64 million.

Raptis Group has entered a facilitation agreement to source funding for the Sterling Residences Broadbeach project, potentially earning up to $16 million in commission fees upon completion and unit settlements.

Brookside Energy Limited reported a strong quarter with the Bruins well commencing production, solid contributions from Gapstow wells, and a disciplined capital strategy including a new share buy-back program.

Beonic Limited reported a landmark $15.2 million contract win in North Africa alongside strong Q4 FY25 EBITDA profitability and positive cash flow, signaling robust operational momentum heading into FY26.

Turners Automotive Group has issued over 324,000 new shares under its Dividend Reinvestment Plan for the FY25 final dividend, slightly increasing its capital base.

PlaySide Studios has raised $6.6 million through a share placement to bolster its balance sheet ahead of the launch of its new original game, MOUSE, P.I. For Hire. The capital raise includes director participation and an upcoming Share Purchase Plan for existing shareholders.

Asara Resources has raised $25 million through a well-supported institutional placement to accelerate exploration at its promising Kada Gold Project in Guinea. The capital injection aims to expand drilling and resource growth over the next 12-18 months.

Stockland updates its interim dividend for the six months ending June 2025, confirming an estimated payout of AUD 0.172 per security and announcing the Dividend Reinvestment Plan price at AUD 5.43 with a 1% discount.

Peak Rare Earths Limited has updated its acquisition scheme, replacing Ganzhou Chenguang with Shenghe Resources (Singapore) Pte. Ltd. as the acquiring party, simplifying regulatory hurdles and valuing the company at nearly A$158 million.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

MAC Copper Limited has scheduled a key court hearing on July 30 to progress Harmony Gold’s recommended acquisition, moving closer to shareholder votes and regulatory approvals.